Resveratrol suppresses colitis and colon cancer associated with colitis

Cancer Prevention Research

Volumn 3, Issue 4, 2010, Pages 549-559

  Cui, Xiangli ^a   Jin, Yu ^a   Hofseth, Anne B ^a   Pena, Edsel ^a   Habiger, Joshua ^a   Chumanevich, Alexander ^a   Poudyal, Deepak ^a   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a   Singh, Udai P ^a   Hofseth, Lorne J ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; GAMMA INTERFERON; PROTEIN P53; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CANCER RISK; CD3+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; COLITIS; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN REGULATION; FEMALE; FOOD; LAMINA PROPRIA; MALE; MESENTERY LYMPH NODE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOGENS; CELL SEPARATION; COLITIS; COLONIC NEOPLASMS; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; PRECANCEROUS CONDITIONS; STILBENES; T-LYMPHOCYTES;

EID: 77950820267     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0117     Document Type: Article

References (67)

1. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-196
2. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009;2: 409-418
3. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 2008; 66:445-454
4. Rocha-Gonzalez HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther 2008;14:234-247
5. Baxter RA. Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation. J Cosmet Dermatol 2008;7:2-7.
6. Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Patents Cardiovasc Drug Discov 2007;2:133-138
7. Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 2008;62:598-605.
8. Gresele P, Pignatelli P, Guglielmini G, et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 2008;138:1602-1608
9. Rakici O, Kiziltepe U, Coskun B, et al. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol 2005;105:209-215
10. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-1252
11. Singh NP, Hegde VL, Hofseth LJ, et al. Resveratrol (trans-3,5,4′- trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 2007;72:1508-1521
12. Imler TJ, Jr., Petro TM. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17(+)IL-10(+) T cells, CD4(-) IFN-γ(+) cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 2009;9:134-143
13. Yoshida Y, Shioi T, Izumi T. Resveratrol ameliorates experimental autoimmune myocarditis. Circ J 2007;71:397-404.
14. Aribal-Kocaturk P, Kavas GO, Buyukkagnici DI. Pretreatment effect of resveratrol on streptozotocin-induced diabetes in rats. Biol Trace Elem Res 2007;118:244-249
15. Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004;67:1399-1410
16. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006;147:873-885
17. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
18. Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol 2003;98:1563-1568
19. Head K, Jurenka JS. Inflammatory bowel disease. Part II. Crohn's disease-pathophysiology and conventional and alternative treatment options. Altern Med Rev 2004;9:360-401.
20. Jin Y, Kotakadi VS, Ying L, et al. American ginseng suppresses inflammation and DNA damage associated with mouse colitis. Carcinogenesis 2008;29:2351-2359
21. Kotakadi VS, Jin Y, Hofseth AB, et al. Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis. Carcinogenesis 2008; 29:1799-1806
22. Haneke KE. trans-Resveratrol: review of toxicological literature. Research Triangle Park (NC): National Institute of Environmental Health Sciences; 2002. p. 1-64.
23. Abd El-Mohsen M, Bayele H, Kuhnle G, et al. Distribution of [3H] trans-resveratrol in rat tissues following oral administration. Br J Nutr 2006;96:62-70.
24. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661
25. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007;2:541-546
26. Denkert C, Koch I, von Keyserlingk N, et al. Expression of the ELAVlike protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 2006;19:1261-1269
27. Singh UP, Singh S, Taub DD, Lillard JW, Jr. Inhibition of IFN-γ-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 2003;171: 1401-1406
28. Birrell MA, McCluskie K, Wong S, et al. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-κB-independent mechanism. FASEB J 2005;19:840-841
29. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008;269: 243-261
30. Verspaget HW, Pena AS, Weterman IT, Lamers CB. Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut 1988;29:223-228
31. Breider MA, Eppinger M, Gough A. Intercellular adhesion molecule-1 expression in dextran sodium sulfate-induced colitis in rats. Vet Pathol 1997;34:598-604.
32. Natsui M, Kawasaki K, Takizawa H, et al. Selective depletion of neutrophils by a monoclonal antibody, RP-3, suppresses dextran sulphate sodium-induced colitis in rats. J Gastroenterol Hepatol 1997; 12:801-808
33. Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2003;100:143-148
34. Clapper ML, Gary MA, Coudry RA, et al. 5-Aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 2008;14:1341-1347
35. Onizawa M, Nagaishi T, Kanai T, et al. Signaling pathway via TNF-α/NF-κB in intestinal epithelial cells may be directly involved in colitisassociated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009;296:G850-9.
36. Suzuki R, Kohno H, Sugie S, et al. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 2006;27:162-169
37. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005;128: 891-906.
38. Chang WC, Coudry RA, Clapper ML, et al. Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Carcinogenesis 2007;28:2375-2381
39. Targan SR. Current limitations of IBD treatment: where do we go from here? Ann N Y Acad Sci 2006;1072:1-8.
40. Zingarelli B, Szabo C, Salzman AL. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 1999;45:199-209.
41. Kankuri E, Vaali K, Knowles RG, et al. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine. J Pharmacol Exp Ther 2001;298:1128-1132
42. Beck PL, Li Y, Wong J, et al. Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation. Gastroenterology 2007;132:1778-1790
43. El-Medany A, Mahgoub A, Mustafa A, et al. The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rof ecoxib, on experimental colitis induced by acetic acid in rats. Eur J Pharmacol 2005;507:291-299
44. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008;118:560-570
45. Murthy S, Flanigan A, Coppola D, Buelow R. RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res 2002;51:522-531
46. Kim YA, Kim GY, Park KY, Choi YH. Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. J Med Food 2007;10:218-224
47. Nunokawa Y, Oikawa S, Tanaka S. Human inducible nitric oxide synthase gene is transcriptionally regulated by nuclear factor-κB dependent mechanism. Biochem Biophys Res Commun 1996;223: 347-352
48. Zamamiri-Davis F, Lu Y, Thompson JT, et al. Nuclear factor-κB mediates over-expression of cyclooxygenase-2 during activation of RAW 264.7 macrophages in selenium deficiency. Free Radic Biol Med 2002;32:890-897 (Pubitemid 34439259)
49. Kim YA, Lim SY, Rhee SH, et al. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells. Int J Mol Med 2006;17:1069-1075
50. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br J Pharmacol 1999;126:673-680
51. Kundu JK, Chun KS, Kim SO, Surh YJ. Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biof actors 2004;21:33-39
52. Kaviani A, Ohta M, Itani R, et al. Tumor necrosis factor-α regulates inducible nitric oxide synthase gene expression in the portal hypertensive gastric mucosa of the rat. J Gastrointest Surg 1997;1:371-376
53. Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995;270:31315-31320
54. Kowalski J, Samojedny A, Paul M, et al. Effect of apigenin, kaempferol and resveratrol on the expression of interleukin-1β and tumor necrosis factor-α genes in J774.2 macrophages. Pharmacol Rep 2005;57:390-394
55. Nakai M, Sudo K, Yamada Y, et al. The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Dig Dis Sci 2005;50:1669-1676
56. Obermeier F, Kojouharof f G, Hans W, et al. Interferon-γ (IFN-γ)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999;116:238-245
57. Gao X, Xu YX, Janakiraman N, et al. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 2001;62:1299-1308
58. Bi XL, Yang JY, Dong YX, et al. Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. Int Immunopharmacol 2005;5:185-193
59. Palmen MJ, Dijkstra CD, van der Ende MB, et al. Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats. Clin Exp Immunol 1995;101:351-356
60. Morohoshi Y, Matsuoka K, Chinen H, et al. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol 2006;41:318-324
61. Tikoo K, Singh K, Kabra D, et al. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008;42:397-404.
62. Lin HY, Sun M, Tang HY, et al. Resveratrol causes COX-2- and p53- dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008;104:2131-2142
63. Heiss EH, Schilder YD, Dirsch VM. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem 2007;282:26759-26766
64. Liontas A, Yeger H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 2004;24:987-998
65. She QB, Bode AM, Ma WY, et al. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 2001;61:1604-1610
66. Hofseth LJ, Ying L. Identifying and defusing weapons of mass inflammation in carcinogenesis. Biochim Biophys Acta 2006;1765:74-84.
67. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-285